18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin
PURPOSE: Metastatic cancers of unknown primary origin are characterised by a poor prognosis, with a survival rate from diagnosis of approximately 12 months. Conventional radiological imaging allows detection of 20%-27% of primary cancers, whereas the detection rate with positron emission tomography (PET) is 24%-40%. The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers.
MATERIALS AND METHODS: The study population consisted of 38 consecutive patients with histologically proven metastatic disease and negative or nonconclusive conventional diagnostic procedures. All patients were studied by 18F-FDG PET performed according to the standard procedure (6 h of fasting, intravenous injection of 370 MBq 18F-FDG, and image acquisition with a PET/CT scanner for 4 min per bed position).
RESULTS: 18F-FDG-PET/CT detected the occult primary cancer in 20 cases (53%), showing higher sensitivity than that reported for any other imaging modality, including PET.
CONCLUSIONS: The encouraging results, if validated by larger series, support the use of PET/CT in patients with carcinoma of unknown primary origin and negative conventional imaging results.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
La Radiologia medica - 111(2006), 8 vom: 15. Dez., Seite 1146-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ambrosini, V [VerfasserIn] |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 14.02.2007 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM167211757 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM167211757 | ||
| 003 | DE-627 | ||
| 005 | 20231223112434.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0557.xml |
| 035 | |a (DE-627)NLM167211757 | ||
| 035 | |a (NLM)17171520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ambrosini, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2007 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Metastatic cancers of unknown primary origin are characterised by a poor prognosis, with a survival rate from diagnosis of approximately 12 months. Conventional radiological imaging allows detection of 20%-27% of primary cancers, whereas the detection rate with positron emission tomography (PET) is 24%-40%. The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers | ||
| 520 | |a MATERIALS AND METHODS: The study population consisted of 38 consecutive patients with histologically proven metastatic disease and negative or nonconclusive conventional diagnostic procedures. All patients were studied by 18F-FDG PET performed according to the standard procedure (6 h of fasting, intravenous injection of 370 MBq 18F-FDG, and image acquisition with a PET/CT scanner for 4 min per bed position) | ||
| 520 | |a RESULTS: 18F-FDG-PET/CT detected the occult primary cancer in 20 cases (53%), showing higher sensitivity than that reported for any other imaging modality, including PET | ||
| 520 | |a CONCLUSIONS: The encouraging results, if validated by larger series, support the use of PET/CT in patients with carcinoma of unknown primary origin and negative conventional imaging results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a Nanni, C |e verfasserin |4 aut | |
| 700 | 1 | |a Rubello, D |e verfasserin |4 aut | |
| 700 | 1 | |a Moretti, A |e verfasserin |4 aut | |
| 700 | 1 | |a Battista, G |e verfasserin |4 aut | |
| 700 | 1 | |a Castellucci, P |e verfasserin |4 aut | |
| 700 | 1 | |a Farsad, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rampin, L |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorentini, G |e verfasserin |4 aut | |
| 700 | 1 | |a Franchi, R |e verfasserin |4 aut | |
| 700 | 1 | |a Canini, R |e verfasserin |4 aut | |
| 700 | 1 | |a Fanti, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Radiologia medica |d 1947 |g 111(2006), 8 vom: 15. Dez., Seite 1146-55 |w (DE-627)NLM000345326 |x 1826-6983 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2006 |g number:8 |g day:15 |g month:12 |g pages:1146-55 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2006 |e 8 |b 15 |c 12 |h 1146-55 | ||